ASLAN Pharmaceuticals Limited (ASLN)

$0.6879

+0.01 (+1.16%)
Rating:
Recommendation:
-
Symbol ASLN
Price $0.6879
Beta 1.631
Volume Avg. 0.22M
Market Cap 47.977M
Shares () -
52 Week Range 0.341-1.16
1y Target Est -
DCF Unlevered ASLN DCF ->
DCF Levered ASLN LDCF ->
ROE -76.67% Strong Sell
ROA -52.26% Strong Sell
Operating Margin -
Debt / Equity 229.08% Strong Buy
P/E -
P/B 2.17 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ASLN news


Dr. Carl Alan Jason Morton Firth
Healthcare
Biotechnology
NASDAQ Global Market

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.